| http://www.w3.org/ns/prov#value | - The group will enroll 60 children between the ages of six and 17 years to study the safety and effectiveness of ganaxolone for treating behaviors and anxiety common with FXS.The fact that a study with ganaxolone was awarded this grant is a testament to the potential for neurosteroid augmentation as a new treatment for FXS patients, stated Gail Farfel, Ph.D., Chief Clinicaland Regulatory Officer
|
